Followers | 834 |
Posts | 120152 |
Boards Moderated | 17 |
Alias Born | 09/05/2002 |
![](https://investorshub.advfn.com/uicon/14742.png?cb=1465058685)
Tuesday, December 14, 2021 7:07:34 PM
https://finance.yahoo.com/news/rinvoq-upadacitinib-receives-u-fda-231800396.html
The second-line restriction (following TNF-a treatment in the first line) is a consequence of the label changes for JAK inhibitors generally in inflammatory diseases (#msg-167001417).
Summary of Rinvoq indications in US and EU:
RINVOQ 15 mg is approved by the U.S. Food and Drug Administration (FDA) for adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers and adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. RINVOQ 15 mg is also approved by the European Commission for adults with moderate to severe active rheumatoid arthritis, adults with active psoriatic arthritis and adults with active ankylosing spondylitis. RINVOQ is approved by the European Commission for adults (15 mg and 30 mg) and adolescents (15 mg) with moderate to severe atopic dermatitis. Phase 3 trials of RINVOQ in rheumatoid arthritis, atopic dermatitis, psoriatic arthritis, axial spondyloarthritis, Crohn's disease, ulcerative colitis, giant cell arteritis and Takayasu arteritis are ongoing.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Recent ABBV News
- Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®) • GlobeNewswire Inc. • 07/28/2024 12:05:00 PM
- AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis • PR Newswire (US) • 07/26/2024 06:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/25/2024 11:41:17 AM
- AbbVie Reports Second-Quarter 2024 Financial Results • PR Newswire (US) • 07/25/2024 11:36:00 AM
- U.S. Index Futures Mixed After Tech Sell-Off, Oil Prices Drop on Weak China Demand and Ceasefire Expectations • IH Market News • 07/25/2024 10:21:35 AM
- AbbVie's EPKINLY™ Receives First-Ever Time-Limited Reimbursement Recommendation by Canada's Drug Agency • PR Newswire (Canada) • 07/23/2024 11:02:00 AM
- L'Agence des médicaments du Canada octroie à AbbVie sa toute première recommandation de remboursement à durée limitée pour EPKINLY (MC) • PR Newswire (Canada) • 07/23/2024 11:02:00 AM
- AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Giant Cell Arteritis • PR Newswire (US) • 07/12/2024 12:30:00 PM
- AbbVie Announces Appointment of Roopal Thakkar, M.D. as Executive Vice President, Research & Development and Chief Scientific Officer • PR Newswire (US) • 07/10/2024 12:00:00 PM
- Tesla Listed for China’s Government Vehicles; Macy’s Acquisition Offer Raised, and More News • IH Market News • 07/05/2024 12:13:34 PM
- AbbVie to Host Second-Quarter 2024 Earnings Conference Call • PR Newswire (US) • 07/02/2024 12:00:00 PM
- Robert A. Michael Assumes Role as AbbVie Chief Executive Officer • PR Newswire (US) • 07/01/2024 12:00:00 PM
- AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma • PR Newswire (US) • 06/28/2024 06:00:00 AM
- AbbVie Acquires Celsius Therapeutics • PR Newswire (US) • 06/27/2024 01:26:00 PM
- Introducing Allē Payment Plans, Powered by Cherry • PR Newswire (US) • 06/27/2024 12:30:00 PM
- U.S. Food and Drug Administration Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma • PR Newswire (US) • 06/26/2024 11:03:00 PM
- AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) • PR Newswire (US) • 06/25/2024 12:15:00 PM
- AbbVie Declares Quarterly Dividend • PR Newswire (US) • 06/21/2024 12:00:00 PM
- AbbVie Appoints Roxanne S. Austin as Lead Independent Director of the Board of Directors • PR Newswire (US) • 06/20/2024 12:00:00 PM
- U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease • PR Newswire (US) • 06/18/2024 10:18:00 PM
- AbbVie Recommends Shareholders Reject Tutanota's "Mini-Tender" Offer • PR Newswire (US) • 06/14/2024 08:08:00 PM
- AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease • PR Newswire (US) • 06/13/2024 11:59:00 AM
- BOTOX® Cosmetic (onabotulinumtoxinA) Reveals 2024 Women Entrepreneur Grant Recipients • PR Newswire (US) • 06/11/2024 12:00:00 PM
- AbbVie Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRα) Expressing Platinum-Sensitive Ovarian Cancer • PR Newswire (US) • 06/06/2024 12:45:00 PM
- SkinMedica® Celebrates 25 Years of Empowering Radiant Skin • PR Newswire (US) • 06/06/2024 12:30:00 PM
FEATURED Cannabix Technologies to Deliver Innovative Breath Logix Alcohol Screening Device to Texas, USA • Jul 29, 2024 9:07 AM
INDEXR AI Merges With Moon Equity Holdings Corp. (MONI), Creating a Leading-edge Technology Company • MONI • Jul 29, 2024 9:59 AM
BNCM AND DELEX UNVEIL POST-MERGER MANAGEMENT PLANS • BNCM • Jul 29, 2024 9:00 AM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM